



SCS
Swiss Chemical
Society

Community News

www.scg.ch

www.chemanager-online.com

SWISS CHEMICAL SOCIETY NEWS

Alain De Mesmaeker, new President of the Society

Dr. *Alain De Mesmaeker* succeeds Peter Kündig as SCS President after four years as Vice-President. Alain took over the new role as of January 1, 2016 and is elected for the next three years.



Alain De Mesmaeker
Syngenta Crop Protection AG
Principal Chemistry Expert, Principal
Syngenta Fellow
Born in Brussels, Belgium (1955)

Alain De Mesmaeker's career in brief

After completing his chemistry studies (Master) at the Catholic University of Louvain-La-Neuve, Alain went on to do a PhD with Professor H.G. Viehe entitled 'Synthesis and thermal isomerisation of capto-dative substituted cyclopropanes'. This work led him to a two-year post-doctoral research at the Weizmann Institute in Israel where he performed the total synthesis of carbacyclic analogues of clavulanic acid using radical reactions, before joining Ciba-Geigy Central Research Laboratories in 1985. He remained for 11 years in the Central Research, working on natural products such as carbohydrates, nucleic acids and on radical chemistry.

Alain became a group leader in 1989 and in 1994 was responsible for combinatorial chemistry research in collaboration with external organisations in the USA. In 1997 he transferred to Crop Protection in the newly formed Novartis Agrobusiness, becoming Head of Chemistry Projects in 2000. On formation of Syngenta he was head of Optimisation Chemistry and subsequently Global Head of Research Chemistry. In 2008 he became Senior Chemistry Expert and was promoted to Principal Fellow in January 2010.

Alain published 90 publications that led to more than 50 patents. Amongst others, he is a committee member of the Bürgenstock EuCheMS Conference on Stereochemistry, the Swiss Chemical Society-Syngenta Symposium on Organic Chemistry, the Jury of the 'Karrer Gold Medal Award' University of Zürich, the Jury of the Ruzicka Prize of ETH Zürich, the Kontaktgruppe für Forschungsfragen KGF, the Werner Foundation and the Belgian Organic Synthesis Symposium (BOSS).

Invitation to the SCS General Assembly 2016

The Board of Directors invites all members of the Swiss Chemical Society and the delegates of its associated societies to the 26th General Assembly.

April 22, 2016, 13.30–14.00h
Lecture Hall G 45, Irchel Campus
University of Zürich, Winterthurerstrasse 190, 8057 Zürich

Agenda

1. Welcome and approval of the agenda
2. Election of the vote counters
3. Minutes of the 25th General Assembly from April 24, 2015 in Basel (published in CHIMIA 5/2015, A305)
4. Annual report 2015 (published in CHIMIA 1-2/2016, A141ff)
5. Financial statement 2015 incl. audit report
6. Discharge the Board
7. Elections
8. News and strategic projects
9. Outlook 2016/17
10. Varia

Motions to the assembly can be submitted until April 10, 2016 to info@scg.ch. A summary of the financial statement 2015 will be published on the homepage as news message after the formal audit.

Swiss Chemical Society (SCS)

Dr. Alain De Mesmaeker
President

David Spichiger
Executive Director

Happy Birthday!

Several of our senior SCS members will celebrate special birthdays in 2016. This gives us the opportunity to warmly congratulate them and wish them many more years with us!

95 Years: Fritz Sulzer, Langenthal

90 Years: Rudolf Anliker-Volkamer, Binningen – René Gebhard, Möriken – Ernst Schumacher-Christ, Bremgarten

85 Years: Peter E. Häfelfinger, Riehen – Kurt Schaffner, Brigels – Alfred Wehrli, Zürich

80 Years: Marcel R. Bühlmann, Schenkon – Rudolf M. Dick, Bern – Helmut Link, Basel – Andreas Ludi, Bern – Rolf Meyer, Zufikon – Walfried Mürner, Arlesheim – Max Ribi, Pontresina – Alexander von Zelewsky, Brissago

75 Years: Wilfried Bauer, Laufenburg – Kaspar F. Burri, Binningen – Gion Calzaferri, Bremgarten – Kaspar Eigenmann, Arlesheim – Janos Fischer, Budapest 10 – Georg Fráter, Ebnat-Kappel – Rudolf Geiger, Bottmingen – Walter Graf, Visp – Heinz Heimgartner, Zürich – Urs Hengartner, Basel – Hans Hollenstein, Zuzwil – Hanspeter Keller, Allschwil – Bernard Liebich, Ascona – Roel Prins, Zürich – Albert Renken, St. Sulpice – Martin Roth, Hölstein – Carl W. Schläpfer, Düringen – Peter Skrabal, Kilchberg ZH – Paul Stoll, Riehen

70 Years: Heinz Berke, Zürich – K.H. Dickel, Lörrach – Rudolf O. Duthaler, Bettingen – Dieter Enders, Aachen – Beat Ernst, Magden – Wolfgang Froestl, Lausanne – Heinz Gäggeler, Brugg – Oreste Ghisalba, Reinach – Jürgen Kinkeldei, Steinach – Bernhard Kräutler, Innsbruck (AT) – Ernst Peter Kündig, Chancy – Othmar Leukart, St. Pantaleon – Roger Malherbe, Muttentz – Helmuth Matt, Schaan – Rudolf Naef, Lupsingen – André Peisker, Mönthal – Alois Püntener, Rheinfelden – Rudolf Schmid, Rheinfelden



Heinz Berke



Kaspar Burri



Rudolf Duthaler



Dieter Enders



Heinz Gäggeler



Oreste Ghisalba



Walter Graf



Bernhard Kräutler




E. Peter Kündig



Othmar Leukart



Helmut Link




Helmut Matt



Rudolf Naef




Jürg Pfister



Roel Prins



Alois Püntener



Max Ribl



Martin Roth



Kurt Schaffner



Willi Schläpfer



Ernst Schumacher



Peter Skrabal



Paul Stoll



Alexander von Zelewsky


A warm welcome to our new members!

Period: 14.11.2015 – 22.01.2016:

Davide Bleiner, Zürich – Thomas Brandl, Rickenbach – Ugo Cataldi, Genève – Ka Wing Chan, Zürich – Michael Dieckmann, Gifp-Oberfrick – Jens Gaitzsch, Basel – Bee Ha Gan, Corminboeuf – Rossella Grillo, Vésenaz – Stefanie Jucker, Zürich – Tunahan Kirabali, Lausanne – Erwin Lam, Obergerlafingen – Kim Larmier, Zürich – Alex Müller, Zürich – Georgian Nedelcu, Kloten – Giovanni Salassa, Genève – Rafael Alejandro Sarmiento Perez, Basel – Gabriel Schäfer, Basel – Tina Sovdat, Aarau – Ramon van der Vlag, Groningen (NL) – Serhii Vasylevskyi, Givisiez – Yuming Wang, Puplinge – Zenghui Wang, Wallisellen – Jürg Zimmermann, Pratteln.

HONORS AND AWARDS

Prof. E Peter Kündig awarded the SCS Honorary Membership




The SCS Award Board and the Board of Directors of the Swiss Chemical Society award the SCS Honorary Membership to **Prof. E. Peter Kündig** for his outstanding contributions to the Swiss chemical community. He is honored in recognition of his research achievements in organic synthesis and catalysis with transition metals during his career but also in recognition of his far-ranging and thoughtful management as president of the Platform Chemistry of the Academy of Natural Sciences in the years 2007–2009 and especially as president of the Swiss Chemical Society in the past six years since 2010.

Springer Heterocyclic Chemistry Award 2016 goes to Jérôme Waser



The Springer Heterocyclic Chemistry Award 2016 has been given to **Prof. Jérôme Waser** from the École Polytechnique Fédérale de Lausanne (EPFL) for his exceptional research achievements. Waser has contributed significantly to the advancement of multiple areas of heterocyclic chemistry, and his highly original work has already had an impact in academia and industry. The award will be presented at the European Colloquium on Heterocyclic Chemistry in Amsterdam from 3 to 6 July 2016. (source: Springer Verlag).

Prof. Dieter Seebach is honored by the Lodz University of Technology



On 2 December, 2015, **Prof. Dieter Seebach** received the award ‘Zasłużony dla Politechniki Łódzkiej’ which translates to ‘Meritorious of the Lodz University of Technology’.

During the ceremonial meeting of the Senate at the Lodz University of Technology on 2 December, 2015, he was presented with the award for the commitment, achievements and passion in his work. The SCS cordially congratulates Prof. Seebach for winning this award! (www.chab.ethz.ch)

Dr. Peter Maienfisch awarded Honorary Professor of East China University of Science and Technology



Jinping Qu, president of the East China University of Science and Technology (ECUST), awarded **Dr. Peter Maienfisch** from Syngenta Crop Protection AG, Basel, Switzerland, with the appointment letter of 'Honorary Professor of East China University of Science and Technology' as well as the university badge.

The 'Honorary Professor Awarding Ceremony' to Dr. Peter Maienfisch was held at Yifu Building on December 1st, 2015. The ceremony was presided over by Gonghua Song, the President assistant of ECUST and the dean of the School of Pharmacy. Jiajun Jiao, dean of the Department of International Affairs, Zhe Wang, general secretary of the School of Pharmacy, Yun Tang, vice dean of the School of Pharmacy and Zhong Li, director of the Institute of Pesticides and Pharmaceuticals and, other professors and students from the School of Pharmacy attended the ceremony. Distinguished guests, Xinling Yang from China Agricultural University, Changling Liu from Shenyang Research Institute of Chemical Industry and Dr. Philip W. Lee from DuPont also attended the ceremony.

Peter Maienfisch then gave a lecture entitled 'Current Challenges and Trends in Crop Protection' emphasizing that he will try his best to promote the development of pesticide-related research and strengthen the collaboration of ECUST with Syngenta. (www.ecust.edu.cn)

Thomson Reuters Announces the World's Most Influential Scientific Minds




Two of the 19 scientists identified by Thomson Reuters as the World's Most Influential Scientific Minds (from all scientific domains) are professors at EPFL, **Prof. Michael Grätzel** (picture) and **Prof. Mohammed Nazeeruddin**.

The Intellectual Property (IP) and Science business of Thomson Reuters, announces the release of 'The World's Most Influential Scientific Minds', a citation analysis identifying the scientists – as determined by their fellow researchers – who have made the most significant global impact within their respective field of study.

The two-part study includes an 11-year assessment of research paper citations to determine the leaders within 21 broad fields of science and a ranking of 2015's top scientists or 'hottest researchers', revealing significant growth in cancer genomics and improvements in converting solar cells into renewable energy. (www.epfl.ch/news)


Promotion of Prof. Roland K. O. Siegel at University of Zürich



Prof. Dr. Roland K. O. Siegel, geb. 1971, wurde auf den 1. Februar 2016 zum ordentlichen Professor für Chemie, insbesondere Bioanorganische Chemie, befördert. Prof. Siegel ist seit 2008 als ausserordentlicher Professor für das gleiche Fachgebiet an der Universität Zürich tätig. (www.chem.uzh.ch)

JOURNAL NEWS

ChemistrySelect – A new home for your research




ChemistrySelect is the latest journal from ChemPubSoc Europe and Wiley-VCH. It offers researchers around the world a quality society-owned journal in which to publish their work. Intended to cover all areas of chemistry, *ChemistrySelect* offers authors broad dissemination of their latest research and guarantees a most rapid peer-reviewed publication. It is free to read for all in 2016. Visit the journal homepage for

more information and submit now! (www.chemistryselect.org)

Prof. Jeffrey Bode and Prof. Christophe Copéret new Editors in Chief of *Helvetica Chimica Acta*



Starting from June 2016, **Prof. Jeffrey Bode** (top picture) and **Prof. Christophe Copéret** (bottom picture) are the new Editors in Chief of the journal *Helvetica Chimica Acta*.



In mid-2016, a fully Swiss-based Board of Editors headed by Profs Jeffrey Bode and Christophe Copéret will relaunch *Helvetica Chimica Acta*. The relaunch comprises new offices in Zurich as well as a complete redesign of the journal.

Happy Birthday *ChemMedChem*!

Issue 01/2016 of *ChemMedChem* marks the 10th anniversary of the journal. With a complete set of 10 volumes, the Editorial Team takes a look back at how *ChemMedChem*, and indeed the field of medicinal chemistry, have evolved and changed over the past decade.

INDUSTRIAL NEWS

Source: www.chemmanager-online.com

Roche Agrees Cancer Partnership with SQZ Biotech

Dec. 09, 2015: Roche and SQZ Biotech are working together to develop a cell therapy platform that would empower patients' own immune cells to fight a broad range of cancers.

SQZ's pioneering technology is based on introducing proteins, or antigens, into patients' B cells which will then help activate killer T cells to attack the cancer. SQZ said its novel approach, which seeks to target tumors more effectively, has the potential to overcome many of the shortcomings of current cell-based therapies.

Under the deal, the US biotech firm, a spin-out of the Massachusetts Institute of Technology (MIT), will get more than \$500 million in upfront and potential clinical, regulatory and sales milestone-based payments as well as royalties on potential future products.

SQZ Biotech is backed by Polaris Venture Partners and 20/20 Healthcare Partners.

Roche Wins Patent Dispute Against Cipla

Dec. 11, 2015: An Indian court has unexpectedly sided with Swiss drugmaker Roche in a long-running patent dispute with Indian generics giant Cipla.

A two-judge panel for the Delhi High Court concluded that Cipla violated a patent for Roche's lung cancer drug Tarceva (erlotinib) and ordered it to pay damages and the Swiss company's legal fees.

The cost to Cipla will be determined at a later date, based to a large degree on the profits made from sales of its generic cancer drug Erllocip, for which the patent was violated.

Commentators said the decision flies in the face of multiple court decisions dating back to 2008 in the long-running case, all of which Cipla had won.

In the Roche decision, the panel said lower court rulings and a division assessment had erred in supporting Cipla's challenge to the patent over a perceived lack of innovation and questions as to whether patent protection extends to different molecular configurations of the same ingredients.

At the same time, the judges declined to grant Roche an injunction to stop Cipla from marketing Erllocip, noting that the Indian patent is due to expire in March 2016.

Cipla has been accused of violating foreign drugmakers' patents in India numerous times. In other 2015 cases, the company is reported to have won a patent challenge against Boehringer Ingelheim in March. Before that, it was successfully parried by an injunction filed by Novartis in January.

ChemChina Improves bid for Syngenta

Dec. 23, 2015: In the latest move to take control of Swiss agrochemicals company Syngenta, ChemChina has raised its bid and proposed a two-step acquisition, international news media report. If successful, the deal would potentially be the biggest-ever purchase by a Chinese company.

Citing people familiar with the matter, Bloomberg said the state-owned Chinese company has offered to buy 70% of Syngenta immediately, with an option to buy the remaining 30%. ChemChina has also offered to buy all of the company at once and has sufficient financing available, the sources added.

ChemChina is seen as offering 470 Swiss francs per share in cash for a 70% stake, valuing Syngenta at \$44 billion. The two-step offer would allow ChemChina to integrate the two businesses before assuming complete control. Last month, the Chinese company was said to have bid 449 francs a share, which Syngenta rejected as being too low.

Talks are reportedly advanced, but Syngenta may also be waiting to see if Monsanto will make a counter offer. The US agribusiness giant abandoned its takeover plans in August of this year, after the Swiss company rebuffed a third bid.

Monsanto's chief operating officer Brett Begemann told reporters last month the company was discussing internally the merits of a new offer for its Swiss rival, as well as opportunities to acquire crop chemical assets from other companies.

A merger with Monsanto would face more regulatory hurdles than a deal with ChemChina which only holds a 5% share of the global market.

Speculation that Syngenta will do a deal has been mounting following this month's merger between Dow Chemical and DuPont, creating the world's largest agriculture business. The move could trigger a wave of consolidation in the agrochemicals industry which is under pressure from fierce competition.

Syngenta's chairman, Michel Demare, told the Swiss newspaper *Finanz und Wirtschaft* the company is also talking to Monsanto again.

"Given what shareholders expect for the next 12 months, going it alone is hardly possible," Demare said. He said the board

was considering making an acquisition, merging with a rival or selling the company.

Separately, in an interview with Dow Jones Newswires, Syngenta's interim CEO, John Ramsay, said the company was prepared to discuss options with the whole industry, including Monsanto; however, "our focus has got to be on the ability to actually believe in the value creation and have the confidence we can pull it off."

Recipharm in Ophthalmic Collaboration with Alcon

Dec. 29, 2015: Swedish drug developer and toll manufacturer Recipharm has signed a long-term agreement with Swiss eye-care treatment company Alcon, part of Novartis, to manufacture a range of ophthalmic products using its Blow Fill Seal technology. Recipharm said the agreement will add annual sales of more than €36 million.

As part of the deal, Recipharm will also acquire full ownership of Kaysersberg Pharmaceuticals for €18 million, with 75% of the sum to be paid this year and the remaining 25% in January 2016. The acquisition, which is being financed with existing funds, is expected to close on Dec. 31.

Kaysersberg's main asset is a manufacturing facility in Kaysersberg, France, which currently supplies the ophthalmic products. The 260 people working at the site will transfer to Recipharm.

Thomas Elderer, Recipharm's CEO, said Blow Fill Seal was a very interesting and growing technology. The process is an injection-molding technique for producing plastic unit doses of sterile drugs.

Bayer Concludes Diabetes Care Sale to Panasonic

Jan. 07, 2016: Bayer has finalized the sale of its Diabetes Care business to Panasonic Healthcare Holdings. The deal, which was previously announced in June last year, was closed on Jan. 5.

The new stand-alone business has been renamed Ascensia Diabetes Care Holdings with its headquarters in Basel, Switzerland.

The sale included the Contour range of blood glucose monitoring systems as well as other products such as Breeze 2, Elite and Microlet lancing devices.

Catalent and Roche Link on SMARTag

Jan. 14, 2016: Redwood Bioscience, a subsidiary of Catalent, a US-based global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has entered a research collaboration with Switzerland's Roche to develop next-generation molecules coupling different therapeutic modalities with the help of Catalent's proprietary protein-modification technology SMARTag.

Catalent said the use of SMARTag, combined with the highly stable hydrazino-Pictet-Spengler conjugation platform, will permit evaluation of alternative sites of drug conjugation to facilitate development of molecules optimized for efficacy, safety and stability.

As part of the deal, Roche will pay Catalent an upfront fee of \$1 million and provide additional research funding during the initial phase of the collaboration. In return, the Swiss drugmaker will gain non-exclusive access to the platform and will have an option to take commercial licenses to develop molecules directed to a defined number of targets.

The US company also could receive up to \$618 million in development and commercial milestones, plus royalties on net sales of products, if Roche pursues commercial licenses and all options are exercised.

Lonza Expands UK Mammalian Production

Jan. 15, 2016: Swiss fine and specialty chemicals producer Lonza has expanded its mammalian production capacity to meet increased demand for biopharmaceutical development and clinical manufacturing services.

Two 1,000 liter single-use bioreactors have been added to its site in Slough, UK, the company's center of excellence for development and clinical supply, significantly increasing capacity.

Lonza said the new reactors, equipped with controllers that enable parallel operations and expanded process capabilities with flexible operating scales and bioreactor types, complement existing single-use equipment for both seed train systems and downstream processing, including chromatography, filtration and ultrafiltration unit operations.

The company added that the technologies support its ability to accommodate a variety of customer projects and processes across scales and clinical phases.

AbbVie Leukemia Drug Under Review

Jan. 19, 2016: Venetoclax, a novel leukemia treatment developed by biopharmaceutical company AbbVie, is to be reviewed by regulators in the US and EU. The drug is described as a potential first-in-class therapy for certain adults with chronic lymphocytic leukemia (CLL). The slow-progressing cancer of the bone marrow and blood and is the most common leukemia diagnosed in adults in western countries.

In the US, the Food and Drug Administration (FDA) has granted venetoclax a priority review for use in patients who have received at least one prior therapy, including those with 17p deletion, a genetic variation in CLL that carries a poor prognosis. With priority review, the FDA's goal is for a review of six months compared with the standard 10-month period.

In Europe, a marketing authorization application for the drug has been validated for treating patients carrying either the 17p deletion or TP53 mutation.

Developed in collaboration with Genentech and Roche, venetoclax is an inhibitor of the B-cell lymphoma-2 (BCL-2) protein. It is believed to lead some cells, including some cells with CLL, to undergo apoptosis, or cell death.

The filings are supported by the results of a Phase II study which AbbVie said met its primary target of achieving an overall response rate with no unexpected safety signals.

Analysts told the news agency Reuters that venetoclax could generate annual sales of \$2 billion by 2020.

NEWS FROM MEMBER SOCIETIES

Zentralkurs Chemie 2015 des Vereins Schweizerischer Naturwissenschaftslehrerinnen und -lehrer (VSN)

Text: Günter Baars, Bern

Schaffhausen 2015

Es ist Mittwoch, der 14. Oktober 2015, früh am Morgen. Der Schreibende hat gerade den Zug, von Bern kommend, verlassen und ist auf dem Weg zum Hotel, um dort seinen Rollkoffer abzuliefern. Auf dem Weg zur Vorgasse kommen ihm kleine Gruppen von Leuten entgegen, die fröhlich grüssen; wir kennen uns.


Über die Bachstrasse und ein kurzes Stück auf der Pestalozzistrasse geht es zu einem grossen Schulkomplex. Die Personen, die einer steilen Treppe zustreben, werden immer zahlreicher und gelangen schliesslich in ein Schulgebäude. Das Gedränge ist gross, die Freude des Wiedersehens ebenfalls.

Über 100 Chemielehrerinnen und Chemielehrer der Schweiz treffen sich zum alle drei Jahre stattfindenden Zentralkurs. Es ist erfreulich, wie intensiv schon jetzt diskutiert und erzählt wird, wie alte Bekanntschaften sich erneuern und neue geschlossen werden. Die Anmeldung und der Bezug der Unterlagen geraten dabei ein wenig in den Hintergrund.

Eine munter schwatzende Schar von Frauen und Männern begibt sich in die Aula zur Begrüssung durch den Hausherrn der Kantonsschule Schaffhausen, den Erziehungsdirektor sowie den Prorektor des Gymnasiums: Chemie, eine Wissenschaft, die einen Beitrag zur Bewältigung der heutigen (Welt-)Probleme leisten kann. Der Chemieunterricht im Rahmen der schulischen Ausbildung spielt deshalb eine wichtige Rolle. Dass sich einer der Redner dabei an den vor einigen Jahren verstorbenen Hans Rudolf Christen erinnert, freut natürlich die älteren Semester unter uns.

Das Programm setzt mit einem fulminanten Vortrag von Prof. Ernst P. Fischer ein: „Die Verzauberung der Welt“. Die Naturwissenschaften, so seine Überlegungen, heben die Geheimnisse dieser Welt nicht auf, sondern vertiefen sie. Natürlich folgt auf jede Antwort auf eine an die Natur gerichtete Frage eine neue Frage. Dies ist auch der Grund, weshalb wir in den Naturwissenschaften, und das gilt im Besonderen für die Chemie, mit Modellen arbeiten: Vorstellungen über Naturphänomene, die nur Teilbereiche der Realität abbilden und weder richtig noch falsch sind, sondern mehr oder weniger zu einem Verstehen beitragen. Dass damit auch das Staunen über die Natur, über die Materie, in den Schülerinnen und Schülern geweckt wird (geweckt werden soll), scheint mir für den Chemieunterricht unerlässlich. Die Botschaft, die Herr Fischer uns mitteilen will, findet sich in einer Äusserung von Johannes Flücke in seinem Aufsatz Rehabilitierung der Sinnestätigkeit: „Voraussetzung des Erfolgs von Unterricht ist, dass der Lehrer selbst Interesse und Freude am Neuentdecken der in den Phänomenen sich dem Menschengestalt darstellenden Fragen hat und um die Unerschöpfbarkeit der Wirklichkeit weiss.“

Nach diesen grundsätzlichen Gedanken zu den Naturwissenschaften und ihrer Vermittlung geht es nun zu konkreten (bio-)chemischen Themen. Prof. Andreas Zumbühl gibt uns in seinem Vortrag „Vesikel Origami“ einen Einblick zur Synthese und Anwendung künstlicher Phospholipide: Lipide, die so gefaltet sind, dass Vesikel Ecken und Kanten aufweisen. Damit erhofft man sich, Medikamente noch gezielter an den Ort im Körper zu bringen, an dem sie ihre Wirkung entfalten sollen.



Der Nachmittag gehört den Workshops. Eine breite Palette an Themen steht zur Auswahl: Von grundsätzlichen Überlegungen zum Grundlagenfach Chemie (chemische Bindung unterrichten –

ohne Oktettregel und Formalladungen) reicht der Fächerkanon über magische Stifte, Naturseifen, Lebensmittelchemie, Herstellung von Gummibärchen, Synthese von Propen zu allgemeineren Themen, wie z.B. Dünnschichtchromatografie, Computerchemie oder mit Skizzen unterrichten. Erhitzte Köpfe, lebhaft Diskussionen und intensive Fachgespräche in den Pausen zeugen von der Aktualität des Dargebotenen.

Die Generalversammlung des VSN ist sehr gut besucht, im Gegensatz zu vielen anderen Vereinsjahresversammlungen.

Der erste Tag klingt bei einem gemeinsamen Nachtessen aus, an dem die Gespräche weitergehen, Kontakte vertieft und erneuert werden, die Chemie nicht mehr unbedingt im Zentrum steht, Persönliches einfließt... „Ladrinengespräche“ halt, die „Seele“ einer Tagung.

Prof. Matthias Ducci ist der Vortragende am Donnerstagmorgen. „Aus den Archiven der CIA“ ist sein Thema. Er entführt uns in die Welt der Spione, der Geheimiten, und damit in eine Welt, die das Licht des Tages scheut. Glänzend die dazu vorgeführten Experimente, die von Frau Dr. Kerstin Brezesinski hervorragend auf die grossen Leinwand projiziert werden.

Nach einer längeren Kaffeepause – mir scheint, die Gespräche nehmen noch an Intensität zu – geht es wieder zu den Workshops: Den Düften auf der Spur, Wir decken unseren Frühstückstisch, Hochalpine Daguerreotypie, Gaschromatografie für jedermann, Chemie und Kunst, Simulationsprogramm für Säure-Base-Chemie, Chemie-Moodle usw.

Nachmittags versammeln wir uns zuerst wieder im Auditorium. Dr. Dieter Muri berichtet über Radioaktivität in Medizin und Pharma. Wir erhalten einen Einblick in die Welt der radioaktiven Nuklide und ihre heilende Wirkung. Ziel dieser Forschung ist eine möglichst schonende Behandlung bei der Krebtherapie. Die Wirkung der ionisierenden Strahlung soll möglichst am Tumor und nicht am umliegenden Gewebe stattfinden.

Die Workshops der Blöcke F und G beschliessen den wissenschaftlichen Teil des Zentralkurses: Elimination von Mikroverunreinigungen aus kommunalem Abwasser, Kunststoff-Analytik im SchülerInnen-Praktikum, Modelle im Chemieunterricht, Das brennende Buch, Mes premiers travaux pratiques de chimie au gymnase, Schüler-Experimente im Kleinmassstab usw.

Es ist dämmrig geworden, die Kolleginnen und Kollegen streben alle dem gleichen Ort zu: Es ist Zeit für den Festabend. Etwas später ankommende Teilnehmer empfängt ein äusserst lebhaftes und lautes Stimmengewirr. Ebenso zufällig wie

auch geplant sind die Gruppen an den verschiedenen Tischen, schmackhaft das Menü und von Herzen kommend der Dank an die Organisatoren sowie die Veranstalter der Workshops.



Die Vergabe des Balmer-Preises rundet den Abend ab. Geehrt wird unser Kollege **Francis Mingard**, Gymnase Nyon (rechts). David Spichiger, Executive Director der SCG (links), übergibt den Preis und verliest die Laudatio: “Dr. Francis Mingard, Gymnase de Nyon, was awarded the 2015 Balmer Prize for the development

of didactic chemistry experiments and for making them available on the web.”

Es ist zu überlegen, eine Preisverleihung im Plenum eines Hörsaals stattfinden zu lassen. An vielen Tischen war die Laudatio nicht zu verstehen und die Experimente, die der Geehrte vorführte, waren kaum zu sehen.

Bei der Rückkehr ins Hotel überkam den Schreibenden das Gefühl, eine grosse, in Freundschaft verbundene Familie zu verlassen. Dies ist das Verdienst von Martin Schwarz und seiner Mannschaft, denen an dieser Stelle nochmals ganz herzlich für die grosse Arbeit gedankt sei.



Das Organisationskomitee um den OK-Präsidenten Martin Schwarz (Zweiter von links).




Get your ticket on www.ilmac.ch as of May 2016
Free entry with the SCS pricocode: ILMAC2016-SCS

ILMAC

Competence in Process and
Laboratory Technology

20 to 23 September 2016 | Messe Basel | www.ilmac.ch



Focused on your success: ILMAC depicts all the industrial applications that feature in process and laboratory technology to a greater extent than any other fair. Make a note of the date right now!